Prevention of coronary heart disease and the National Cholesterol Education Program.

نویسنده

  • Lewis H Kuller
چکیده

The incubation period for the progression of atherosclerosis to clinical disease is long, which provides an opportunity for risk factor modification and prevention of coronary heart disease (CHD). The National Cholesterol Education Program (NCEP) utilized the Framingham risk score (FRS) to classify individuals by level of risk to receive drug therapy and/or dietary counseling to lower low-density lipoprotein cholesterol (LDL-C) and raise highdensity lipoprotein cholesterol (HDL-C). The rationale for choosing specific cutpoints for treatment was based on 3 key variables: (1) the efficacy of drug therapy to reduce the CHD incidence, (2) the safety of drug therapy, and (3) the cost of therapy.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

The National Cholesterol Education Program Adult Treatment Panel Iii—how Do Women Fit In?

The National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) released initial guidelines in 1988 (ATP I), followed by ATP II in 1993 and ATP III in 2001. In ATP I and II, treatment recommendations and goals of therapy for secondary prevention are similar. However, ATP III established a more aggressive approach for both secondary prevention and higher risk primary-prevention pat...

متن کامل

Preventive strategies for reducing coronary heart disease-related morbidity and mortality in patients with multiple risk factors.

Based on epidemiologic and clinical evidence, the National Cholesterol Education Program Adult Treatment Panel has identified low-density lipoprotein cholesterol as the primary target for lipid intervention to promote the reduction of high cholesterol through increased awareness and aggressive management of cardiovascular risk factors. These guidelines provide the basis for management of multip...

متن کامل

Digoxin in heart failure: results of the recent Digoxin Investigation Group trial in the context of other treatments for heart failure.

[6] Shepherd J, Cobbe SM, Ford I et al, for The West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7. [7] The Expert Panel. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Me...

متن کامل

Prevalence of major coronary heart disease risk factors in Iran

Background and aims: Coronary heart diseases (CHDs) contribute to mortality, morbidity, disability, productivity and quality of life. This study was aimed to determine the prevalence of major risk factors for CHD in the provinces of Iran. Methods: This study reported pre-existing data and was of secondary, descriptive type. Prevalence of non-communicable disease (NCD) risk factors was def...

متن کامل

Using the Framingham model to predict heart disease in the United Kingdom: retrospective study.

table for cholesterol lowering for primary prevention of coronary heart disease. Lancet 1995;346:1467-71. 14 Ramsay LE, Haq IU, Jackson PR, Yeo WW, Pickin DM, Payne JN. Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table. Lancet 1996;348:387-8. 15 Haq IU, Ramsay LE, Jackson PR, Wallis EJ. Prediction of coronary risk for primary prevention...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Circulation

دوره 113 5  شماره 

صفحات  -

تاریخ انتشار 2006